Decibel Therapeutics (NSDQ:DBTX) recently presented preclinical data for DB-OTO at the Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO). DB-OTO is a dual-vector adeno-associated virus (AAV) investigational gene therapy product candidate for individuals with hearing loss from mutations of the otoferlin gene. The most recent data showed that otoferlin expression increased for…